Skip to main content
Top
Published in: BMC Health Services Research 1/2022

Open Access 01-12-2022 | Human Papillomavirus | Research article

Supporting the implementation of new healthcare technologies by investigating generalisability of pilot studies using area-level statistics

Authors: James Alexander Doorbar, Christopher S. Mathews, Karin Denton, Matejka Rebolj, Adam R. Brentnall

Published in: BMC Health Services Research | Issue 1/2022

Login to get access

Abstract

Background

Implementation of new technologies into national health care systems requires careful capacity planning. This is sometimes informed by data from pilot studies that implement the technology on a small scale in selected areas. A critical consideration when using implementation pilot studies for capacity planning in the wider system is generalisability. We studied the feasibility of using publicly available national statistics to determine the degree to which results from a pilot might generalise for non-pilot areas, using the English human papillomavirus (HPV) cervical screening pilot as an exemplar.

Methods

From a publicly available source on population indicators in England (“Public Health Profiles”), we selected seven area-level indicators associated with cervical cancer incidence, to produce a framework for post-hoc pilot generalisability analysis. We supplemented these data by those from publicly available English Office for National Statistics modules. We compared pilot to non-pilot areas, and pilot regimens (pilot areas using the previous standard of care (cytology) vs. the new screening test (HPV)). For typical process indicators that inform real-world capacity planning in cancer screening, we used standardisation to re-weight the values directly observed in the pilot, to better reflect the wider population. A non-parametric quantile bootstrap was used to calculate 95% confidence intervals (CI) for differences in area-weighted means for indicators.

Results

The range of area-level statistics in pilot areas covered most of the spectrum observed in the wider population. Pilot areas were on average more deprived than non-pilot areas (average index of multiple deprivation 24.8 vs. 21.3; difference: 3.4, 95% CI: 0.2–6.6). Participants in HPV pilot areas were less deprived than those in cytology pilot areas, matching area-level statistics. Differences in average values of the other six indicators were less pronounced. The observed screening process indicators showed minimal change after standardisation for deprivation.

Conclusions

National statistical sources can be helpful in establishing the degree to which the types of areas outside pilot studies are represented, and the extent to which they match selected characteristics of the rest of the health care system ex-post. Our analysis lends support to extrapolation of process indicators from the HPV screening pilot across England.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10:67.CrossRefPubMedPubMedCentral Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol. 2010;10:67.CrossRefPubMedPubMedCentral
2.
go back to reference Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020;6:167.CrossRefPubMedPubMedCentral Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020;6:167.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed
5.
go back to reference Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18:1–196.CrossRef Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18:1–196.CrossRef
6.
go back to reference Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240.CrossRefPubMedPubMedCentral Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240.CrossRefPubMedPubMedCentral
7.
go back to reference Rebolj M, Brentnall AR, Mathews C, Denton K, Holbrook M, Levine T, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer. 2019;121:455–63.CrossRefPubMedPubMedCentral Rebolj M, Brentnall AR, Mathews C, Denton K, Holbrook M, Levine T, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer. 2019;121:455–63.CrossRefPubMedPubMedCentral
9.
go back to reference Peris M, Espinas JA, Munoz L, Navarro M, Binefa G, Borras JM, et al. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007;14:81–6.CrossRefPubMed Peris M, Espinas JA, Munoz L, Navarro M, Binefa G, Borras JM, et al. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain). J Med Screen. 2007;14:81–6.CrossRefPubMed
10.
go back to reference U. K. Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ. 2004;329:133. U. K. Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ. 2004;329:133.
11.
go back to reference Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut. 2017;66:1631–44.CrossRefPubMed Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut. 2017;66:1631–44.CrossRefPubMed
12.
go back to reference Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J Med Screen. 2008;15:143–8.CrossRefPubMed Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J Med Screen. 2008;15:143–8.CrossRefPubMed
13.
go back to reference Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20:1–146.CrossRefPubMedPubMedCentral Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20:1–146.CrossRefPubMedPubMedCentral
14.
go back to reference Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, et al. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Eur J Cancer. 2016;68:148–55.CrossRefPubMed Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, et al. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Eur J Cancer. 2016;68:148–55.CrossRefPubMed
15.
go back to reference Lamin H, Eklund C, Elfstrom KM, Carlsten-Thor A, Hortlund M, Elfgren K, et al. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. BMJ Open. 2017;7:e014788.CrossRefPubMedPubMedCentral Lamin H, Eklund C, Elfstrom KM, Carlsten-Thor A, Hortlund M, Elfgren K, et al. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. BMJ Open. 2017;7:e014788.CrossRefPubMedPubMedCentral
16.
go back to reference Lam JU, Rebolj M, Moller Ejegod D, Pedersen H, Rygaard C, Lynge E, et al. Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms. Int J Cancer. 2017;140:2212–9.CrossRefPubMedPubMedCentral Lam JU, Rebolj M, Moller Ejegod D, Pedersen H, Rygaard C, Lynge E, et al. Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms. Int J Cancer. 2017;140:2212–9.CrossRefPubMedPubMedCentral
17.
go back to reference Keiding N. The Method of Expected Number of Deaths, 1786–1886-1986. Int Stat Review. 1987;55:1–20.CrossRef Keiding N. The Method of Expected Number of Deaths, 1786–1886-1986. Int Stat Review. 1987;55:1–20.CrossRef
18.
go back to reference Keiding N, Clayton D. Standardization and Control for Confounding in Observational Studies: A Historical Perspective. Statistical Sci. 2014;29:529–58.CrossRef Keiding N, Clayton D. Standardization and Control for Confounding in Observational Studies: A Historical Perspective. Statistical Sci. 2014;29:529–58.CrossRef
19.
go back to reference Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol. 2014;38:174–80.CrossRefPubMed Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol. 2014;38:174–80.CrossRefPubMed
20.
go back to reference Green LI, Mathews CS, Waller J, Kitchener H, Rebolj M. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing. Int J Cancer. 2021;148:1850–7.CrossRefPubMed Green LI, Mathews CS, Waller J, Kitchener H, Rebolj M. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing. Int J Cancer. 2021;148:1850–7.CrossRefPubMed
21.
go back to reference Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H. Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. BJOG. 2022;129:1278–88.CrossRefPubMed Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H. Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. BJOG. 2022;129:1278–88.CrossRefPubMed
22.
go back to reference Rebolj M, Mathews CS, Denton K. Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot. Cancer Cytopathol. 2022;130:531–41.CrossRefPubMedPubMedCentral Rebolj M, Mathews CS, Denton K. Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot. Cancer Cytopathol. 2022;130:531–41.CrossRefPubMedPubMedCentral
23.
go back to reference Rebolj M, Mathews CS, Pesola F, Castanon A, Kitchener H. Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study. Int J Cancer. 2022;150:1412–21.CrossRefPubMed Rebolj M, Mathews CS, Pesola F, Castanon A, Kitchener H. Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study. Int J Cancer. 2022;150:1412–21.CrossRefPubMed
24.
go back to reference Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022;127:278–87.CrossRefPubMedPubMedCentral Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022;127:278–87.CrossRefPubMedPubMedCentral
25.
go back to reference Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer. 2011;105:983–8.CrossRefPubMedPubMedCentral Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer. 2011;105:983–8.CrossRefPubMedPubMedCentral
29.
go back to reference Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016;115:1140–6.CrossRefPubMedPubMedCentral Landy R, Pesola F, Castanon A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016;115:1140–6.CrossRefPubMedPubMedCentral
30.
go back to reference Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383:1340–8.CrossRefPubMed Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383:1340–8.CrossRefPubMed
31.
go back to reference Falcaro M, Castanon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084–92.CrossRefPubMed Falcaro M, Castanon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084–92.CrossRefPubMed
32.
go back to reference Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014;135:453–66.CrossRefPubMed Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer. 2014;135:453–66.CrossRefPubMed
34.
go back to reference Lam JU, Rebolj M, Dugue PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21:38–50.CrossRefPubMed Lam JU, Rebolj M, Dugue PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21:38–50.CrossRefPubMed
35.
go back to reference Aral SO. Sexual risk behaviour and infection: epidemiological considerations. Sex Transm Infect. 2004;80 Suppl 2:ii8–12. Aral SO. Sexual risk behaviour and infection: epidemiological considerations. Sex Transm Infect. 2004;80 Suppl 2:ii8–12.
36.
go back to reference Massat NJ, Douglas E, Waller J, Wardle J, Duffy SW. Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. BMJ Open. 2015;5:e007735.CrossRefPubMedPubMedCentral Massat NJ, Douglas E, Waller J, Wardle J, Duffy SW. Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. BMJ Open. 2015;5:e007735.CrossRefPubMedPubMedCentral
37.
go back to reference Rebolj M, Parmar D, Maroni R, Blyuss O, Duffy SW. Concurrent participation in screening for cervical, breast, and bowel cancer in England. J Med Screen. 2020;27:9–17.CrossRefPubMed Rebolj M, Parmar D, Maroni R, Blyuss O, Duffy SW. Concurrent participation in screening for cervical, breast, and bowel cancer in England. J Med Screen. 2020;27:9–17.CrossRefPubMed
42.
go back to reference Hakama M, Malila N, Dillner J. Randomised health services studies. Int J Cancer. 2012;131:2898–902.CrossRefPubMed Hakama M, Malila N, Dillner J. Randomised health services studies. Int J Cancer. 2012;131:2898–902.CrossRefPubMed
43.
go back to reference Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd edition). Philadelphia, PA: Lippincott Williams & Wilkins; 2008. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd edition). Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
44.
go back to reference Blanks RG, Moss SM, Denton K. Improving the NHS cervical screening laboratory performance indicators by making allowance for population age, risk and screening interval. Cytopathology. 2006;17:323–38.CrossRefPubMed Blanks RG, Moss SM, Denton K. Improving the NHS cervical screening laboratory performance indicators by making allowance for population age, risk and screening interval. Cytopathology. 2006;17:323–38.CrossRefPubMed
46.
go back to reference Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical cancer screening in England. J Med Screen. 2022;29:203-8. Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical cancer screening in England. J Med Screen. 2022;29:203-8.
Metadata
Title
Supporting the implementation of new healthcare technologies by investigating generalisability of pilot studies using area-level statistics
Authors
James Alexander Doorbar
Christopher S. Mathews
Karin Denton
Matejka Rebolj
Adam R. Brentnall
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2022
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-022-08735-3

Other articles of this Issue 1/2022

BMC Health Services Research 1/2022 Go to the issue